Real-world use of PCSK9 inhibitors: A single-center experience

OBJECTIVE: Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease. Many patients are intolerant to or have limited benefit from statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been approved for treating hyperlipidemia in these patients. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarsam, Sinan, Berry, Abeer, Degheim, George, Singh, Robby, Zughaib, Marcel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Clinical Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384467/
https://www.ncbi.nlm.nih.gov/pubmed/30280628
http://dx.doi.org/10.1177/0300060518800595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384467/
https://www.ncbi.nlm.nih.gov/pubmed/30280628
http://dx.doi.org/10.1177/0300060518800595

Ejemplares similares